The Department of Health and Social Care (DHSC) has redetermined January, August, and October 2025 reimbursement prices for the eight products to reflect an increase in their NHS list prices.
Community Pharmacy England (CPE) has stated that it had earlier made several representations on behalf of community pharmacy owners and this intervention would help prevent community pharmacies from losing an estimated £58,000 to medicine price rises.
To avoid pharmacy owners dispensing these medicines at a loss, DHSC has agreed to grant retrospective price adjustments.
The medicines slated for the October 2025 adjustment are as follows:
Maxijul Super Soluble powder (Nutricia Ltd), 25000 grams pack size, redetermined price £244.47 (previous price £234.85)
Phlexy-Vits powder 7g sachets (Nutricia Ltd), 30 sachet pack size, £107.70 (£103.50)
Phlexy-Vits tablets (Nutricia Ltd), 180 tablets pack size, £124.24 (£119.35)
PKU Anamix Junior powder 36g sachets neutral (Nutricia Ltd), 30 sachets pack size, £191.70 (£184.20)
Complete Amino Acid Mix powder (Nutricia Ltd), 200 gm pack size, £142.93 (£137.30)
They all fall under the Non Drug Tariff category.
August 2025 price adjustments
Colomycin 1million unit powder for solution for injection vials (Teva UK Ltd), 10 vials pack size, £33.98 (£18.00)
Colomycin 2million unit powder for solution for injection vials (Teva UK Ltd), 10 vials pack size, £54.96 (£32.40)
January 2025 price adjustments
Ilube 5% eye drops (Rayner Pharmaceuticals Ltd), 10 ml pack size, £92.75 (£80.95)
The drugs adjusted in August 2025 and January 2025 come under Part VIIIA Category C.
CPE is awaiting confirmation from DHSC as to when pharmacy owners can expect to receive their adjusted payments for the above items.
The payments will appear as ‘Adjustment drugs' and ‘Adjustment fees’ (if applicable).
CPE sought price adjustments to several other products affected by NHS list price increases in August 2025, but the DHSC has granted price redeterminations for eight of them.
The delays in reimbursement prices catching up with any NHS list price increases can lead to dispensing at a loss, as pharmacies will be reimbursed based on the previous NHS list price until the price change is adjusted in line with the price change timetable.
The impact is more significant for products with large list price increases or for high-volume lines.
